Clinical Trial Update: Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating chemotherapy de-escalation in early-stage HER2-positive breast cancer has been withdrawn from the study registry.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: University of Rochester | Conditions: HER2-positive Breast Cancer | Phase 2 | Status: WITHDRAWN